In vitro antibacterial activities of new fluoroquinolones against clinical isolates of Haemophilus influenzae with ciprofloxacin-resistance-associated alterations in GyrA and ParC

Chemotherapy

Volumn 50, Issue 6, 2004, Pages 265-275

  Yoshizumi, Satoshi ^a,b   Takahashi, Yoshie ^b   Watanabe, Yoshinari ^b   Okezaki, Eiichi ^b   Ishii, Yoshikazu ^a   Tateda, Kazuhiro ^a  

^a TOHO UNIVERSITY   (Japan)

^b Abbott Japan Co Ltd   (Japan)

Author keywords

Ciprofloxacin resistant; Haemophilus influenzae; Quinolones

Indexed keywords

ANTIINFECTIVE AGENT; ASPARAGINE; ASPARTIC ACID; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; GLUTAMIC ACID; LEUCINE; LYSINE; NUCLEOTIDE; OLAMUFLOXACIN; PROTEIN PARC; QUINOLONE DERIVATIVE; SERINE; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CORRELATION ANALYSIS; DRUG POTENCY; ENZYME PURIFICATION; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; GENES, BACTERIAL; HAEMOPHILUS INFLUENZAE; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION;

EID: 11344252881     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082624     Document Type: Article

References (35)

1. Yamaguchi K, Ohno A, Kashitani F, Iwata M, Shimizu Y, Itoh M, Tsujio Y, Tachibana M, Matsuda K, Takaya H, Nakamura T, Sugimoto K, Toyoshima S, Sato S, Matsumoto I, Funato T, Nagasawa M, Kanno H, Okada J, Igari J, Oguri T, Okada M, Nakai T, Ichiyama S, Asari S, Toyokawa M, Yamanaka K, Kuwabara M, Murase M, Takemori K, Tadano J, Nagasawa Z: In vitro activity of 23 antimicrobial agents against 4,993 gram-positive and gram-negative bacterial strains isolated from multicenter of Japan during 1994 - in vitro susceptibility surveillance. Jpn J Antibiot 1999;52:75-92.
2. Ikemoto H, Watanabe K, Mori T, Igari J, Oguri T, Terai T, Inoue H, Nakadate T, Ito C, Yoshida T, Ohno I, Okada S, Arakawa M, Igarashi K, Okada M, Ozaki K, Aoki N, Kitamura N, Sekine O, Suzuki Y, Nakata K, Nakatani T, Inagawa H. Kudo K, Kondo T, Kobayashi H, Kawai S, Takayasu S, Shimada K, Nakano K, Takamori M, Yokouchi H, Ito A, Sumitomo M, Matsushima T, Niki Y, Ando M, Suga M, Sato K, Tosaka M, Kohno S, Tomono K, Hirakata Y, Izumikawa K, Yamaguchi T, Mochida C, Nasu M, Ito M, Yamasaki T, Nakano T, Saito A, Touyama M, Yamane N, Kusano N: Susceptibility of bacterial isolated from patients with lower respiratory infectious diseases to antibiotics (1997). Jpn J Antibiot 1999;52:353-397.
3. Takahashi T, Tsujihara Y, Shimura H, Hachiya K, Takahashi S, Harada M, Takahashi S, Matsumoto F: Antimicrobial activities of β-lactam antibiotics against clinically isolated Haemophilus influenzae. Jpn J Antibiot 1999;52:292-301.
4. Yamaguchi K, Miyazaki S, Kashitani F, Iwatani M, Watanabe N, Uehara N, Sasaki T, Yoshida K, Sato N, Yoshida H, Imafuku Y, Wada K, Igari J, Oguri T, Kobayashi Y, Katohno Y, Totsuka K, Shimada J, Kanemitsu K, kaku M, Waki S, Hashizume I, Yamanaka K, Matsushima T, Niki Y, Miyashita N, Yoshida K, Kono S, Miyazaki Y, Matsuda J, Hirakata Y, Ono J, Takata T, Matsunaga T, Nomura A: Susceptibility of clinical isolates from Japan to trovafloxacin and other antimicrobial agents. Jpn J Chemother 2001;49:241-256.
5. Baquero F: Trends in antibiotic resistance of respiratory pathogens: An analysis and commentary on a collaborative surveillance study. J Antimicrob Chemother 1996;38(suppl A):117-132.
6. Derecola A, Butler DL, Kaplan RL, Miller LA, Poupard JA: A 5-year surveillance study of 44,691 isolates of Haemophilus influenzae project beta-alert 1993-1997. Antimicrob Agents Chemother 1999;43:185-186.
7. Marco F, García-DE-Lomas J, García-Rey C, Bouza E, Aguilar L, Fernández-Mazarrasa C: The Spanish Surveillance Group for Respiratory Pathogens. Antimicrob Agents Chemother 2001;45:3226-3228.
8. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN: Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001;32(suppl 2):S81-93.
9. Dhar R, Wilson S, Ghafoor M, Rotimi VO, Chugh TD: Present status of antimicrobial susceptibility of Haemophilus influenzae isolates in Kuwait as determined by E-test. Med Principles Pract 2001;10:123-128.
10. Johnson DM, Sader HS, Fritsche TR, Biedenbach DJ, Jones RD: Susceptibility trends of Haemophilus influenzae and Moraxella catarrhalis against orally administrated antimicrobial agents: Five-year report from the SENTRY antimicrobial Surveillance Program. Diagn Microbial Infect Dis 2003;47:373-376.
11. Takahashi Y, Masuda N, Otsuki M, Miki M, Nishino T: In vitro activity of HSR-903, a new quinolone. Antimicrob Agents Chemother 1997;41:1326-1330.
12. Yoshizumi S, Domon H, Miyazaki S, Yamaguchi K: In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens. Antimicrob Agents Chemother 1998;42:785-788.
13. Yoshizumi S, Takahashi T, Murata M, Domon H, Furuya N, Ishii Y, Matsumoto T, Ohno A, Tateda K, Miyazaki S, Yamaguchi K: The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infection in mice. J Antimicrob Chemother 2001;48:137-140.
14. Georgiou M, Muñoz R, Román F, Cantón R, Gómez-lus R, Campos J, Campa A GDL: Ciprofloxacin-resistant Haemophilus influenzae strains possess mutation in analogous positions of GyrA and ParC. Antimicrob Agents Chemother 1996;40:1741-1744.
15. Bootsma HJ, Troelstra A, Veen-Rutgers AV, Mooi FR, Neeling AJD, Overbeek BP: Isolation and characterization of a ciprofloxacin-resistant isolates of Haemophilus influenzae from The Netherlands. J Antimicrob Chemother 1997;39:292-293.
16. Vila J, Ruiz J, Sanchez F, Navarro F, Mirelis B, Anta MTJD, Prats G: Increase in quinolone resistance in Haemophilus influenzae strains isolated from a patient with recurrent respiratory infections treated with ofloxacin. Antimicrob Agents Chemother 1999;43:161-162.
17. Biedenbach DJ, Jones RN: Fluoroquinolone-resistant Haemophilus influenzae: Frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America). Diagn Microbial Infect Dis 2000;36:255-259.
18. Japanese Society of Chemotherapy: Revision of minimal inhibitory concentration (MIC) determination method. Chemotherapy (Tokyo) 1981;29:76-79
19. Maniatis T, Fritsch EF, Sambrook J: Molecular cloning: A laboratory manual. Cold Spring Harbor, Cold Spring Harbor Laboratory, 1982, vol 1-3.
20. Fleischmann RD, Adams MD, White O, et al: Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 1995;269:496-512.
21. Suzuki Y, Nishinari C, Endo H, Tamura C, Jinbo K, Hiramatsu N, Akiyama K, Koyama T: Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000. II. Gram-negative bacteria. Jpn J Antibiot 2002;55:154-180.
22. Ubukata K, Hasegawa K, Chiba N, Kobayashi R, Konno M: Community-Acquired Bacterial Infectious Working Group: Surveillance based on molecular epidemiology for Haemophilus influenzae isolated between 1998 and 2000 in Japan. Results of clinical isolates collected by the Community-Acquired Bacterial Infectious Working Group. Chemotherapy (Tokyo) 2002;50:794-804.
23. Bell JM, Turnidge JD, Pfaller MA, Jones RD: In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolated from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-1999). Diagn Microbial Infect Dis 2002;43:315-318.
24. Madhusudhan KT, Counts C, Lody C, Carter O, Dodson S, Ojha N: Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test. Chemotherapy (Basel) 2003;49:184-188.
25. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, ed 5. Approved Standard M7-A5. Wayne, NCCLS, 2000.
26. Japanese Society of Chemotherapy: The breakpoint MICs in respiratory tract infections and sepsis. Chemotherapy (Tokyo) 1994;42:905-914.
27. Murata M, Tamai I, Sai Y, Nagata O, Kato H, Tsuji A: Carrier-mediated lung distribution of HSR-903, a new quinolone antibacterial agent. J Pharmacol Exp Ther 1999;289:79-84.
28. Mizuno A, Umemura K, Nakashima M: Pharmacokinetics and safety of HSR-903 in healthy volunteers. Program and Abstract of the Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans. Washington, American Society for Microbiology, 1996, abstr F59: 110.DC.
29. Seki H, Kasahara Y, Ohta Ku, Ohta Ka, Saikawa Y, Sumita R, Yachie A, Fujita S, Koizumi S: Increasing prevalence of ampicillin-resistant, non-β-lactamase-producing strains of Haemophilus influenzae in children in Japan. Chemotherapy (Basel) 1999;45:15-21.
30. Ohkusu K, Nakamura A, Sawada K: Antibiotic resistance among recent clinical isolates of Haemophilus influenzae in Japanese children. Diagn Microbial Infect Dis 2000;36:249-254.
31. Sakata H: Antimicrobial susceptibility of Haemophilus influenzae isolated from children with respiratory tract infection. Chemotherapy (Tokyo) 2002;51:569-573.
32. Danišovičová A, Brezina M, Belan S, Kayserová H, Kayserová E, Hruškovič I, Orosová K, Dluholucký S, Gaľova K, Mathéova E, Marinová I, Krčméry VJ: Magnetic resonance imaging in children receiving quinolones: No evidence of quinolone-induced arthropathy: A multicenter survey. Chemotherapy (Basel) 1994;40:209-214.
33. Chyský V, Kapila K, Hullman R, Arcieri G, Schacht P, Echols R: Safety of ciprofloxacin in children: Worldwide clinical experience based on compassionate use. Emphasis on joint evaluation. Infection 1991;19:289-296.
34. Chalumeau M, Tonnelier S, Athis PD, Tréluyer JM, Gendrel D, Bréart G, Pons G, the Pediatric Fluoroquinolone Safety Study Investigators: Fluoroquinolone safety in pediatric patients: A prospective, multicenter, comparative cohort study in France. Pediatrics 2003;111:715-719.
35. Sazawal S, Black RE, Pneumonia Case Management Trial Group: Effect of pneumonia case management on mortality in neonates, infants, and preschool children: A meta-analysis of community-based trials. Lancet Infect Dis 2003;3:547-556.